ROSEAId Inc
ROSEAId Inc is a private AI healthcare company that operates a cloud-based telepathology platform, providing remote diagnostic, research, and Pathology-as-a-Service solutions to pathologists, teaching hospitals, research institutions, and underserved healthcare providers globally.
- Company typePrivate
- Founded2020
- HeadquartersBlauvelt, United States
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
What ROSEAId Inc does
ROSEAId Inc is a private AI healthcare company founded in 2020, headquartered in Blauvelt, New York, with additional offices in Houston (representative) and Abu Dhabi (regional Middle East headquarters). The company was established through a collaboration with the University of Texas Health Science Center and has built a cloud-based AI telepathology platform, branded ROSE AI, that enables remote diagnosis, collaboration, and analysis for pathologists and clinical laboratories. Its core technology stack rests on a proprietary Multi-Modal Large Language Foundational Model (MMLLM) that integrates textual and visual data from pathology images, supported by a Knowledge Engine, a Digital Twin ecosystem for continuous improvement, and federated learning for data privacy across distributed healthcare systems.
The company operates a three-product portfolio: the Telepathology Platform (clinical diagnostics and workflow), the Research Platform (generative AI and knowledge engineering for teaching hospitals and pharmaceutical research), and Pathology as a Service (PAAS), a managed-service delivery model for remote and underserved healthcare providers via HIPAA-compliant mobile medical centers. Revenue is generated primarily through enterprise subscription licensing, custom quote-based annual contracts, and managed-services fees for PAAS. Distribution is executed via direct enterprise sales targeting large healthcare providers, academic medical centers, and research institutions, supplemented by a regional distributor network covering the Middle East, Africa, Asia (Korea, Singapore), and Latin America/Caribbean through partners including STIGroup Limited LLC, STSC Global Asia, and StrongHer Consulting. Validated technical outcomes include 92.5% accuracy in AI-ROSE evaluation of EUS-FNA specimens and 93.25% accuracy in a unified lesion model, with published research in the Journal of the American Society of Cytopathology.
ROSEAId Inc firmographics
Firmographics- Name
- ROSEAId Inc
- Legal name
- ROSEAId Inc
- Website
- https://roseaid.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- ROSEAId Inc is a private AI healthcare company that operates a cloud-based telepathology platform, providing remote diagnostic, research, and Pathology-as-a-Service solutions to pathologists, teaching hospitals, research institutions, and underserved healthcare providers globally.
- Ownership category
- akta.pro rank
ROSEAId Inc industry classification
Industry- Product category
- Digital Pathology Software
- NAICS
- Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services (5182), Custom Computer Programming Services (541511), Scientific Research and Development Services (5417)
- SIC
- Services-Prepackaged Software (7372), Services-Computer Programming, Data Processing, Etc. (7370)
- akta.pro primary industry
- Virtual Care Team Collaboration & Provider-to-Provider Teleconsult Platforms (eConsults) (HLALABAI)
- akta.pro secondary industries
- Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO), Virtual Specialty Care Platforms (tele-stroke, tele-ICU, tele-derm, tele-cardiology) (HLALABAD), Diagnostic/Lab & Imaging Referral Marketplaces (HLALALAG)
Keywords
Where ROSEAId Inc is headquartered
LocationHeadquarters
- HQ city
- Blauvelt
- HQ country
- United States
- HQ region
- North America
Offices5 records
Markets served
ROSEAId Inc business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Infrastructure, Operations
Revenue model
- Telepathology Platform Software: Cloud-based AI-powered telepathology platform subscription and licensing model for pathologists, healthcare providers, and laboratories to enable remote diagnosis, collaboration, and streamlined workflows.
- Research Platform Services: Cloud-based software solution for teaching hospitals and research laboratories providing generative AI, knowledge engineering, and digital pathology capabilities.
- Pathology as a Service (PAAS): On-demand remote pathology services providing diagnostic insights without extensive infrastructure requirements. Includes remote diagnosis, second opinions, and access to certified pathologists.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise platform licensing with customizable modules for clinical, educational, pharmaceutical research, and laboratory workflows |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
ROSEAId Inc product offering
Product offeringCore offering
ROSEAId builds and sells a cloud-based AI-powered telepathology platform that enables remote analysis, real-time collaboration, and diagnostic decision support for pathologists. It offers three interconnected product lines: a Telepathology Platform for clinical diagnostics, a Research Platform for academic and pharmaceutical research, and Pathology as a Service (PAAS) for on-demand remote pathology services. The platform is built on a proprietary Multi-Modal Large Language Foundational Model (MMLLM) with federated learning, a Knowledge Engine, and a Digital Twin ecosystem.
Product overview
ROSEAId Inc offers a unified platform portfolio of three interconnected AI-powered telepathology solutions: the Telepathology Platform for clinical diagnostics, the Research Platform for academic and pharmaceutical research, and Pathology as a Service (PAAS) for remote service delivery. All solutions share a common Multi-Modal Large Language Foundational Model (MMLLM) architecture, cloud-based infrastructure, and integrate with electronic health records and hospital systems. The platforms work together to serve clinical, educational, and research domains with seamless data flow between use cases.
Differentiator
Problem solved
Functional benefit
Brands
- ROSE AI: AI-powered telepathology platform that revolutionizes digital pathology using AI-driven, cloud-based technology for academia, research and clinical requirements.
Products and services
- Telepathology Platform (ROSE AI) Cloud-based, AI-powered telepathology platform enabling remote pathology analysis and real-time collaboration for pathologists and clinical laboratories. Includes AI-ROSE for rapid onsite evaluation of EUS-FNA specimens, unified model analysis with demonstrated 92.5%–93.25% accuracy, glass slide digitization, workflow optimization, and integration with EHRs and third-party devices.
- Research Platform Cloud-based software solution for teaching hospitals and research laboratories bringing Generative AI, Knowledge Engineering, and Digital Pathology capabilities. Features the Multi-Modal Large Language Foundational Model (MMLLM), Digital Twin ecosystem, and federated learning to support cancer detection, drug discovery, precision medicine research, and integration with hospital management systems.
- Pathology as a Service (PAAS) On-demand managed remote pathology service providing diagnostic insights, second opinions, slide digitization, specialized expertise access, and 24x7 access to certified pathologists without extensive infrastructure. Includes HIPAA-compliant mobile medical centers with internet/satellite connectivity, EHR integration, and access to global pathologist networks for underserved and remote populations.
Quantifiable outcome
- AI-ROSE accuracy of 92.5% in EUS-FNA specimen evaluation
- +3 more outcomes
Companies that use ROSEAId Inc
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles4 records
ROSEAId Inc technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration4 records
AI capability11 records
Feature7 records
ROSEAId Inc partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and minor.
- Premium Africa HoldingscoreStrategic partnership to bring AI pathology suite of early cancer detection solutions to underserved markets in Africa and the Middle East.
- MikroscancorePartnership leveraging Mikroscan's advanced telemicroscopy technology to optimize digital pathology workflows for cancer detection and enhance patient care globally.
- StrongHer Consulting LLCminorStrategic partnership to drive global investment and humanitarian impact in early cancer detection, covering Caribbean, Latin America, and Africa markets.
- RYAILITI (AI Platform)coreAI platform partner using biomimetic engineering and digital twin technology to turn data into actionable insights, optimizing processes and reducing bias across industries.
- Egality SciencesminorU.S.-based partner providing rural communities access to clinical trials, supporting local investigators and industry partners, and leveraging data to advance medical research.
- RoadDocminorPartner via TrueTelemedicine platform offering real diagnostics, continuity of care, and AI-enhanced decision support for underserved populations, anytime, anywhere.
- STS CorporationminorSupports medical and life sciences companies with FDA regulatory services and government contracting to accelerate compliant global expansion.
- University of Texas Health Science Center (UTH)coreCollaboration advancing colorectal cancer screening through AI-driven platform using high-quality training data and clinical insights. Features secure, scalable web-based interface with digital pathology viewer and streamlined consult workflow.
Scale indicators3 records
Recent moves7 records
Expansion highlights6 records
ROSEAId Inc competitors and assessment
Company assessmentDirect peers
- PathAI: PathAI develops AI-powered pathology diagnostics and research tools for pharma and clinical labs, targeting the same pathologist/biopharma buyer with cloud-based image analysis — directly comparable to ROSEAId's telepathology and research platforms.
- Visiopharm: Visiopharm provides AI-driven image analysis and digital pathology solutions for research and clinical labs; comparable to ROSEAId's pathology AI workflow and research tooling.
- Aiforia: Aiforia develops AI image analysis software for pathology and other biomedical imaging, with a cloud platform for research and clinical workflows; overlapping customer base and use cases with ROSEAId.
- Paige AI: Paige builds AI applications for digital pathology with FDA-cleared prostate cancer detection; competes head-to-head with ROSEAId in clinical AI diagnostics and pharma research collaborations.
- Proscia: Proscia provides a cloud-native digital pathology platform (Concentriq) for diagnostic and research workflows, with AI partnerships — a direct competitor to ROSEAId's cloud telepathology platform.
- Owkin: Owkin combines federated learning AI with pathology and oncology research, partnering with academic medical centers and pharma — comparable to ROSEAId's MMLLM/federated learning research platform approach.
- Ibex Medical Analytics: Ibex offers AI-based cancer detection for pathology labs with multi-tumor support and Galen platform; directly overlaps ROSEAId's clinical AI pathology positioning and pathologist customer base.
Emerging players
- OptraScan: OptraScan offers digital pathology scanners and AI-driven workflow tools for clinical and research labs; a smaller emerging peer with overlapping telepathology infrastructure plays.
- Mikroscan: Mikroscan builds telemicroscopy hardware and digital pathology workflows; already a ROSEAId integration partner but a comparable emerging play in the same telepathology ecosystem.
Broad incumbents
- Akoya Biosciences: Akoya is a public, established spatial biology and digital pathology company whose Phenoptics platform competes more broadly across pathology workflows — an incumbent overlapping with ROSEAId's research and clinical pathology focus.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
ROSEAId Inc social profiles
Digital presenceROSEAId Inc compliance and trust
Trust signalCompliance1 record
ROSEAId Inc financial estimates
Financial estimateRevenue estimate
Valuation estimate
ROSEAId Inc leadership team
Management profileNumber of profiles
Profiles12 records
ROSEAId Inc funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ROSEAId Inc M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ROSEAId Inc
What does ROSEAId Inc do?
ROSEAId builds and sells a cloud-based AI-powered telepathology platform that enables remote analysis, real-time collaboration, and diagnostic decision support for pathologists. It offers three interconnected product lines: a Telepathology Platform for clinical diagnostics, a Research Platform for academic and pharmaceutical research, and Pathology as a Service (PAAS) for on-demand remote pathology services. The platform is built on a proprietary Multi-Modal Large Language Foundational Model (MMLLM) with federated learning, a Knowledge Engine, and a Digital Twin ecosystem.
Is ROSEAId Inc a public or private company?
ROSEAId Inc is a private company. It is classified as venture growth investor backed and is currently operating.
When was ROSEAId Inc founded?
ROSEAId Inc was founded in 2020. It employs 51 to 100 people.
Where is ROSEAId Inc based?
ROSEAId Inc is headquartered in Blauvelt, United States, in the North America region.
How does ROSEAId Inc make money?
Three revenue lines are on record. Telepathology Platform Software is the primary driver. The others are research Platform Services and pathology as a Service (PAAS).
Who are ROSEAId Inc's main competitors?
Direct peers on record are PathAI, Visiopharm, Aiforia, Paige AI, Proscia, Owkin and Ibex Medical Analytics. Emerging players are OptraScan and Mikroscan. Akoya Biosciences is listed as a broad incumbent.
Does ROSEAId Inc have an API?
No public API is recorded for ROSEAId Inc.
What industry is ROSEAId Inc in?
ROSEAId Inc's product category is Digital Pathology Software. Its primary akta.pro industry code is HLALABAI, Virtual Care Team Collaboration & Provider-to-Provider Teleconsult Platforms (eConsults), with a secondary code of HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays). Its NAICS code is 5182 and its SIC code is 7372.